AGP Executive Report
Last update: 9 hours agoRett syndrome breakthrough (EU): Acadia’s DAYBU® (trofinetide) won a positive CHMP recommendation for approval in the EU to treat neurobehavioral symptoms of Rett syndrome in adults and children aged 5+. If the European Commission follows, it would be the first EU therapy for this specific indication, based mainly on the Phase 3 LAVENDER study showing improvements on key symptom scales. Bladder cancer care (EU): Merck/MSD’s Keytruda® plus Padcev® secured EU approval for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, using a perioperative approach (before and after surgery) and reporting major gains in event-free survival and pathologic complete response. Breast cancer option (EU): Gilead’s Trodelvy® (sacituzumab govitecan) was approved by the European Commission as first-line monotherapy for certain adults with unresectable or metastatic triple-negative breast cancer not eligible for PD-(L)1 inhibitor therapy. Heat and schools (Europe): A record heatwave is forcing schools to close or shorten days across parts of Europe, with limited cooling options leaving classrooms struggling to protect children. Travel health reminder (UK/EU): Luton Airport warned holidaymakers returning to Great Britain that some meat and dairy items from the EU are illegal to bring back, with confiscation and possible fines.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
